Concord Medical Services Holdings Ltd (CCM) - Company Analysis

Company Overview

Concord Medical Services Holdings Ltd operates primarily in the healthcare sector, focusing on radiotherapy and diagnostic imaging services. The company is based in China and is recognized for its network of radiotherapy centers. Each American Depositary Share (ADS) represents thirty Class A ordinary shares of the company.

Corporate Structure

• Employee Count: 19 employees
• Key Personnel:
  • General Manager: 陳昌華, responsible for overseeing operations and strategic direction.
  • Board Member: Kong Y Yap, affiliated with Legion Healthcare Partners, contributing to governance and strategic decisions.

Recent Developments and News

As of October 2023, there have been no specific announcements or developments reported in the financial news regarding Concord Medical Services. However, the company is actively traded on the New York Stock Exchange (NYSE) under the ticker symbol CCM, with a current stock price of $7.5450, reflecting a 25.54% increase. The trading volume stands at 135,210 shares.

Financial and Strategic Aspects

• Stock Performance: The stock price has increased by 25.54%.
• Funding Milestone: In April 2020, the company secured $100.6 million in post-IPO equity funding.

Key Financial Metrics

• Current Stock Price: $7.5450
• Market Activity: Listed on NYSE
• Trading Volume: 135,210 shares

Market Position and Industry Context

Concord Medical Services operates in a competitive healthcare market in China, focusing on specialized services in radiotherapy and diagnostic imaging. While specific competitors were not identified, the company faces competition from both local and international healthcare providers. The emphasis on advanced diagnostics aligns with trends in healthcare, which prioritize accessible and quality medical care.

TL;DR

Concord Medical Services Holdings Ltd, trading under the ticker CCM on the NYSE, has a current stock price of $7.5450, reflecting a 25.54% increase with a trading volume of 135,210 shares. The company has a workforce of 19 employees and is led by General Manager 陳昌華. In April 2020, it secured $100.6 million in funding. The company operates in a competitive healthcare market in China, focusing on radiotherapy and diagnostic imaging services.